His extensive and unique expertise will help guide in carrying out our strategic objectives in developing cannabinoid therapeutics," Aitan Zacharin, CEO of GCANRx said. Aran is a visionary who has received worldwide acclaim for his pivotal cannabinoid clinical research. In addition, Aran is the director of pediatric neurology at Shaare Zedek Medical Center in Jerusalem. Adi Aran, M.D., head of pediatric neurology at Shaare Zedek Medical center, to further the research and development of unique product formulations.Īran is a physician, scientist, respected key opinion leader and inventor of the cannabinoid neuropsychiatric therapeutic that the Greater Cannabis Company has licensed from Shaare Zedek Scientific Ltd. (OTC:GCAN), a biopharmaceutical company pioneering the development of next-generation cannabinoid therapeutics, recently revealed that it has appointed Dr. Greater Cannabis Company Names Cannabinoid Researcher Dr. "His deep background in cannabis and manufacturing best practices, coupled with his intellectual property expertise, will be invaluable as we grow our product line and expand into new markets," Eichten said. Maigread Eichten, the company's CEO, said he is thrilled that Scott has agreed to join Coda's board. Scott is a founder and former CEO of PharmaCann, who has more than two decades of experience in the cannabis industry, biotechnology research, and intellectual property law. Scott, Ph.D., J.D to serve on the board of directors. Producer of cannabis-infused edibles and wellness products Coda Signature recently appointed Teddy C.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |